Current Report Filing (8-k)
January 08 2018 - 8:33AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 8, 2018
CYTOMX THERAPEUTICS, INC.
(Exact name of Registrant as Specified in Its Charter)
|
|
|
|
|
Delaware
|
|
001-37587
|
|
27-3521219
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
151 Oyster Point Blvd.
Suite 400
South San
Francisco, CA 94080
(Address of principal executive offices, including Zip Code)
Registrants telephone number, including area code: (650)
515-3185
Check the appropriate box below if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions (see General Instructions A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17 CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to Rule
13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule
12b-2
of the Securities Exchange Act of 1934
(§240.12b-2
of this chapter).
Emerging growth company
☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended
transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act.
☒
Item 7.01
|
Regulation FD Disclosure
|
Spokespersons of CytomX Therapeutics, Inc. plan to present the information in
the presentation slides attached hereto as Exhibit 99.1 at various investor meetings scheduled during the week of January 8, 2018. A copy of the presentation, including a slide setting forth certain cautionary language intended to qualify the
forward-looking statements included in the presentation, is furnished as Exhibit 99.1 to this Current Report and is incorporated herein by reference.
The
information in this Item 7.01, including Exhibit 99.1, shall not be deemed filed for purposes of Section 18 of the Security Exchange Act of 1934, as amended (the Exchange Act) or otherwise subject to the liabilities of
that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01.
|
Financial Information and Exhibits
|
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its
behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
Date: January 8, 2018
|
|
|
|
CYTOMX THERAPEUTICS, INC.
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ Debanjan Ray
|
|
|
|
|
|
|
Debanjan Ray
|
|
|
|
|
|
|
Chief Financial Officer
|
CytomX Therapeutics (NASDAQ:CTMX)
Historical Stock Chart
From Mar 2024 to Apr 2024
CytomX Therapeutics (NASDAQ:CTMX)
Historical Stock Chart
From Apr 2023 to Apr 2024